Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Andrey Mastykin
Andrey Mastykin

AstraZeneca stock rises 2.4% as nine-month and third-quarter 2026 results

AstraZeneca stock rises 2.4% as nine-month and third-quarter 2026 results
AstraZeneca stock rises 2.4% today

AstraZeneca will provide its nine-month and third-quarter 2026 performance update to investors on 30 October. The stock is up 2.4% on the day at GBX12,928.

AZN price prediction
24H 0.64%
GBX 14,087
48H 1.36%
GBX 14,189
7D 2.23%
GBX 14,310
1M 7.37%
GBX 15,029
3M 18.02%
GBX 16,520.8
6M 30.44%
GBX 18,258.93
12M 4.48%
GBX 14,624.65
Detailed
Current price: GBX 13,998 946.00 7.25%
Real-time Data 16:29
Daily range 13308.00 Arrow from to Icon 14002.00
Weekly range 12642.00 Arrow from to Icon 14002.00
Loading...

Highlights

  • AstraZeneca will provide its nine-month and third-quarter 2026 financial update to investors on 30 October 2026.
  • Analysts target earnings of $2.59 per share and quarterly revenue of $16.02 billion for AstraZeneca.
  • 77 of 94 analysts rate AstraZeneca stock a buy, with a median price target 23.9% above current levels.

AstraZeneca will release its nine-month and third-quarter 2026 financial results on 30 October 2026. The company will also host a webcast for investors and analysts that day. According to American Market News, analysts expect earnings of $2.59 per share and revenue of $16.02 billion for the quarter.

Bullish structure holds as price tests resistance and overbought signals

Price is sitting right at resistance from the weekly high at GBX12,980. The daily move aligns with the broader bullish chart structure, with the price below the MA-200 but above both the MA-20 and MA-50, highlighting a split structure on the daily chart. Stoch RSI is in overbought territory, which is a stretched reading that limits room for further upside.

Upside odds dominate as traders watch for a close above resistance

Traders should watch whether shares can close above GBX12,980 to assess if buyers are willing to follow through. Price is currently testing resistance at this weekly high and has yet to clear it. After a contained move within a narrow range over the past week, there is a 77% probability of an upside move and a 23% probability of downside for the coming trading week, with an expected trading range between GBX12,623 and GBX13,232. A close above GBX12,980 would show buyers are willing to follow through, while a drop below GBX12,298 would indicate the move is being faded. On the weekly chart the longer-term picture stays constructive.

Earlier, analysts noted that AstraZeneca was likely to remain in a consolidation phase, supported by advances in its clinical pipeline and AI-driven research initiatives. As the stock tests resistance at GBX12,980 ahead of the upcoming earnings release, traders should monitor this key level for confirmation of a breakout or a potential reversal within the projected GBX12,623–GBX13,232 trading range.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

How German metalworkers’ strikes are testing Europe’s industrial strength
  • By Dmytro Kharkov
  • 31 min ago
How German metalworkers’ strikes are testing Europe’s industrial strength
Editors' Picks
DeFi for the select few: Why Hyperliquid is building restricted markets
  • By Pavlo Kot
  • Yesterday
DeFi for the select few: Why Hyperliquid is building restricted markets
Editors' Picks
Can Bitcoin make you a millionaire?
  • By Pavlo Kot
  • 31.10.2026
Can Bitcoin make you a millionaire?
Editors' Picks
All Editors' Top Picks

Latest AstraZeneca News

Can robust earnings and new restructuring support AstraZeneca stock?
  • By Igor Krasulya
  • 39 min ago
Can robust earnings and new restructuring support AstraZeneca stock?
Stocks
#Forecast #UK #AstraZeneca
London FTSE 100 heads for first monthly gain in three months as AstraZeneca lifts pharma stocks
  • By Oleksii Zaichenko
  • 30.10.2026
London FTSE 100 heads for first monthly gain in three months as AstraZeneca lifts pharma stocks
Stocks
#Business #Pharmaceutical Industry #FTSE 100 #AstraZeneca
AstraZeneca shares technical analysis: Upward price move as GBX13,252 resistance nears
  • By Viktoras Karapetjanc
  • 30.10.2026
AstraZeneca shares technical analysis: Upward price move as GBX13,252 resistance nears
Stocks
#Forecast #UK #AstraZeneca
All AstraZeneca News
  • Dmytro Kharkov
  • 31 min ago
How German metalworkers’ strikes are testing Europe’s industrial strength
  • Pavlo Kot
  • Yesterday
DeFi for the select few: Why Hyperliquid is building restricted markets
  • Pavlo Kot
  • 31.10.2026
Can Bitcoin make you a millionaire?
  • Olena Litvinenko
  • 30.10.2026
France's crypto market matures as regulation reshapes the industry
  • Dmytro Kharkov
  • 30.10.2026
SK Hynix’s rise reshapes the global chip industry and economy
  • Elena Nikulina
  • 36 min ago
Crypto and stablecoin transaction tax approved by slim margin, Gregory Raymond notes
  • Mikhail Vnuchkov
  • 36 min ago
Robert Peston: Questions raised on growth and debt reduction plans in budget discussion
  • Mykhailo Ihnatenko
  • 1 hour ago
Ethereum offers neutrality and censorship resistance, Joseph Lubin states
  • Yaroslav Dmytrenko
  • 1 hour ago
Securing the environment is key before Binance resumes, Yi He says
  • Eugene Komchuk
  • 1 hour ago
Mario Nawfal: U.S. healthcare spending rose to $5.3 trillion in 2024
Top News
  • Olga Shendetskaya
  • 44 min ago
Gulf states urge Washington to avoid new confrontation with Iran
Gulf states urge Washington to avoid new confrontation with Iran
  • Eugene Komchuk
  • 1 hour ago
Binance customers withdraw $5.8 billion in wake of hack
Binance customers withdraw $5.8 billion in wake of hack
  • Jose Antonio Gastelum
  • 21 hours ago
OPEC set to hold oil quotas as Middle East risks constrain supply
OPEC set to hold oil quotas as Middle East risks constrain supply
  • Ezequiel Gomes
  • 22 hours ago
Big Tech selloff drives investors back toward U.S. Treasuries
Big Tech selloff drives investors back toward U.S. Treasuries
  • Sholanke Dele
  • 23 hours ago
Binance resumes crypto withdrawals after $6.3B hack
Binance resumes crypto withdrawals after $6.3B hack
Live News
  • Mykhailo Ihnatenko
  • Now
Ethereum price struggles above $2,300 despite $63M whale purchase
  • Andrey Mastykin
  • Now
Eurozone economy slows as France slips into recession fears
  • Anton Kharitonov
  • Now
EUR/USD recovery stalls near 1.1210 as dollar retains its fundamental advantage
  • Anastasiia Chabaniuk
  • Now
Binance launches stolen asset recovery and allocates $6.34 billion to cover losses
  • Mykhailo Ihnatenko
  • Now
AMD stock drops over 7% as Intel outlook hits semiconductor sentiment
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers